Related Experiment Video

Updated: Aug 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

SU11248 and AG013736: current data and future trials in renal cell carcinoma

Brian I Rini1

  • 1Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA. rinib2@ccf.org

Clinical Genitourinary Cancer
|January 24, 2006
PubMed

Insights

Small-molecule tyrosine kinase inhibitors targeting VEGF and PDGF pathways show significant clinical activity in metastatic renal cell carcinoma (RCC). Further investigations are ongoing for these promising agents in various treatment settings.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell carcinoma (RCC) pathogenesis involves molecular pathways like von Hippel-Lindau (VHL) gene inactivation.
  • VHL inactivation leads to overexpression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).

Purpose of the Study:

  • To investigate the efficacy of small-molecule inhibitors targeting VEGF and PDGF receptors in metastatic RCC.
  • To evaluate the clinical activity of SU11248 and AG013736 in various settings of renal cell carcinoma.

Main Methods:

  • Utilizing small-molecule inhibitors (SU11248 and AG013736) that target the tyrosine kinase domain of VEGF and PDGF receptors.
  • Conducting clinical trials in patients with metastatic renal cell carcinoma.

Main Results:

  • Substantial clinical activity observed for SU11248 and AG013736 in metastatic RCC patient cohorts.
  • These agents demonstrated promising therapeutic potential in early-stage investigations.

Conclusions:

  • Small-molecule tyrosine kinase inhibitors targeting VEGF and PDGF signaling pathways are effective in treating metastatic RCC.
  • Ongoing investigations aim to further define the role of these agents in diverse clinical scenarios for renal cell carcinoma.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...